Skip to content

menu

Rothwell, Figg, Ernst & Manbeck, P.C. logo
HomeAboutContact
Rothwell Figg's

Biosimilars Law Bulletin

RegulatoryLegalNews

RFEM’s Biosimilars Inter Partes Review (IPR) Dashboard

RF-Generic-Logo-sm
By Nicole Gifford & Benjamin R. Holt on November 14, 2018
Posted in Legal

RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar products.

Tags: abatacept, adalimumab, Avastin®, bevacizumab, Enbrel®, etanercept, Featured, Herceptin®, Humira®, IPR, Legal, Natalizumab, Neulasta®, News, Orencia®, pegfilgrastim, PTAB, Rituxan®, Rituximab, trastuzumab, Tysabri®, USPTO
Print:
EmailTweetLikeLinkedIn
Related Posts
  • Medical business or prices concept. Making money in pharmaceutical industry or high medical expenses. Dollar sign written with pills spilled from a medicine bottle.Key Members of Congress Urge USPTO to Curtail Discretionary Denials of IPR Petitions to Help Lower Drug Costs by Breaking Patent Thickets
  • Wooden cube with word GUIDELINES on light background. Concept image.Chinese Patent Linkage, Patent Term Adjustment, and Patent Term Extension Guidelines Unveiled For Comments
  • Colorful maze on green background. Labyrinth of colorful wooden blocks, top view, flat lay.Getting Lost in the Thicket: AbbVie Wields Its Expansive Humira® Patent Portfolio Against Alvotech’s Adalimumab Biosimilar
  • Gavel on Chinese flag, Chinese lawPatent Term Extension Introduced by the Fourth Amendment to the Chinese Patent Law
  • Healthcare in Brazil concept, 3D rendering isolated on white backgroundBrazilian Supreme Court Ends Patent Term Extension and Retroactively Cuts Pharmaceutical and Medical Device Patent Terms

Blog Editors

Photo of E. Anthony FiggE. Anthony FiggMember
Photo of Joseph A. HyndsJoseph A. HyndsMember
Photo of Jennifer P. NockJennifer P. NockMember
Photo of Aydin H. HarstonAydin H. HarstonMember

About this Blog

Authored and edited by attorneys in Rothwell Figg’s Biologics and Biosimilars Group, Rothwell Figg’s Biosimilars Law Bulletin provides updates, articles, and analyses regarding regulatory issues, legal decisions, and other news related to biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA).

Read More....

Stay Connected

RSS LinkedIn Twitter Facebook
Subscribe to this blog

Topics

Archives

Blog Authors Show/Hide

  • D. Lawson Allen
  • Nicole M. DeAbrantes
  • Rachel M. Echols
  • Aydin H. Harston
  • Spencer J. Johnson
  • Monica Chin Kitts
  • Alvin Lee
  • Daniel R. McCallum
  • Jennifer P. Nock
  • Andrew J. Storaska
  • Anjali Jenna (AJ) Teigen
  • Richard E. Waterman
  • Caitlin M. Wilmot

Recent Posts

  • Key Members of Congress Urge USPTO to Curtail Discretionary Denials of IPR Petitions to Help Lower Drug Costs by Breaking Patent Thickets
  • Chinese Patent Linkage, Patent Term Adjustment, and Patent Term Extension Guidelines Unveiled For Comments
  • Changes to the Purple Book: Progress in Transparency
  • ‘The Sky is [Not] Falling,’ Federal Circuit Urges as it Continues to Dismantle Broad Pharmaceutical Patents
  • Getting Lost in the Thicket: AbbVie Wields Its Expansive Humira® Patent Portfolio Against Alvotech’s Adalimumab Biosimilar

Rothwell Figg Blogs

  • Privacy Zone
  • PTAB Law Blog
  • RF EMerge
Rothwell, Figg, Ernst & Manbeck, P.C.
Washington, DC
607 14th St. NW
Suite 800
Washington, DC 20005
202.783.6040
info@rfem.com
Boston
One Boston Place
Suite 2600
Boston, MA 02108
617.312.3101
info@rfem.com
RSS LinkedIn Twitter Facebook
Privacy PolicyDisclaimer

About Our Firm

To learn more about our firm and other practice areas, visit www.rfem.com.

Copyright © 2021, Rothwell, Figg, Ernst & Manbeck, P.C.. All Rights Reserved.
Powered By LexBlog